STAT

Schizophrenia ‘risk genes’ are not so risky if the mother’s pregnancy was healthy

Regions of the genome that raise the risk of schizophrenia do so only slightly if the mother experiences no complications during pregnancy — but by some twelvefold if she does.

Far be it from us to tell 23andMe how to run its business, but if it or any other DNA company wants to give customers a better read of disease risk, they might start asking how mom’s pregnancy went.

That’s the key message of a schizophrenia study, published Monday, which showed that 108 regions of the genome previously identified as raising the risk of schizophrenia do so only slightly if the mother experiences no complications during pregnancy — but by some twelvefold if she does.

Taking into

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks